Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00539409 · ClinicalTrials.gov registry record · Phase 2
Effects of Pulsatile Intravenous Insulin Therapy on Metabolic Integrity in Patients With Diabetes Mellitus
A Phase 2 study, sponsored by Florida Atlantic University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 152
- Enrollment target
NCT00539409: Clinical Trial Phase 2 study, sponsored by Florida Atlantic University.
NCT00539409 is a Phase 2 study that was terminated before completion, run by Florida Atlantic University. The registered enrollment target is 152 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00539409, a Phase 2 study, was terminated before completion, sponsored by Florida Atlantic University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 152 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if restoring normal metabolic function in patients with either type I or type II diabetes can improve the impact of the consequences of diabetic complications on the overall quality of life of diabetic patients. Patients are treated once a week with pulsatile intravenous insulin therapy mimicking normal insulin secretion. A diabetic quality of life questionnaire is completed prior to the start of the treatment and quarterly thereafter with detailed analysis performed to measure progress and outcomes
Interventions
- PROCEDURE Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2006-11 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Why NCT00539409 stopped before completion
NCT00539409 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% higher).
The record links to 0 conditions, and to 1 intervention - of which Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog) is the first listed.
NCT00539409 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00539409 about?
NCT00539409 is a clinical study titled "Effects of Pulsatile Intravenous Insulin Therapy on Metabolic Integrity in Patients With Diabetes Mellitus". The purpose of this study is to determine if restoring normal metabolic function in patients with either type I or type II diabetes can improve the impact of the consequences of diabetic complications on the overall quality of life of diabetic patients. Patients are treated once a week with pulsatil...
What is the current status of trial NCT00539409?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 152 participants. The study started on 2006-11. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00539409?
The interventions under investigation include: Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog) (PROCEDURE).
Who is sponsoring clinical trial NCT00539409?
This trial is sponsored by Florida Atlantic University, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00539409's enrollment target sits among peer trials
152 452nd of 2000 higher than 1,547 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia